Open access
Sep 2026
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.
Findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors, and are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts.
Y. Kuboki, T. Koyama, M. Ikeda et al.
· Cancer immunology research · 0 citations